Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
Recruiting
Observational Study
Breast Cancer Female
Stage II Breast Cancer
Stage III Breast Cancer
HER2-positive Breast Cancer
Triple Negative Breast Cancer
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Female
- Study type
- Observational
- Participants needed
- 125 (estimated)
- Sponsor
- Gene Solutions · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment.
* Determine the rate of ctDNA positivity at the time before treatment,
* Determine the rate of ctDNA positivity at the time during treatment,
* Determine the rate of ctDNA positivity at the time after neoadjuv…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female,18 years old and older,
* Are diagnosed with stage II-III HER2+/Triple Negative breast cancer and indicated for neoadjuvant chemotherapy,
* FFPE sample is available at the time of diagnosis and operation,
* Are voluntary to participate in the study.
Exclusion Criteria:…
Contacts